<DOC>
	<DOCNO>NCT00289016</DOCNO>
	<brief_summary>The primary objective study assess clinical efficacy talimogene laherparepvec term tumor response rate .</brief_summary>
	<brief_title>A Study Talimogene Laherparepvec Stage IIIc Stage IV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Patients histologically proven stage IIIc ( include two palpable lymph node , extracapsular intransit metastasis ) stage IV melanoma eligible curative surgery one tumor accessible direct injection . 2 . Tumors 0.5 10 cm long diameter suitable injection ( i.e . bleed weep ) . 3 . Serum lactate dehydrogenase ( LDH ) level ≤ 2.0 time upper limit normal . 4 . Aged 18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . 6 . Clinically immunocompetent . 7 . Recovered prior therapy least 4 week since last exposure chemotherapy radiotherapy . 8 . Total white cell count ≥ 3.0 x 10^9/L , platelet count ≥ 80 x 10^9/L . 9 . Serum creatinine ≤ 0.2 mmol/L . 10 . Bilirubin ≤ 1.5 time upper limit normal range , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) equal less twice upper limit normal range alkaline phosphatase equal less twice upper limit normal range . 1 . Participation previous melanoma immunotherapy trial within one month prior entry trial trial investigational agent within last month prior entry trial . 2 . Tumors inject lie mucosal region close airway , major blood vessel spinal cord , opinion Investigators , could cause occlusion compression case tumor swell erosion major vessel case necrosis . 3 . Pregnancy , lactation lack effective contraception woman childbearing potential ; lack effective contraception men partner childbearing potential ; woman must practise effective contraceptive method least three month prior entry trial ( hormonal contraception intrauterine device conjunction barrier method OR surgically sterilise ) . Men must use condom surgically sterilise . 4 . Major surgery within 14 day prior entry trial . 5 . Intercurrent serious infection within 28 day prior entry trial . 6 . Lifethreatening illness unrelated cancer . 7 . Treatment antiviral agent within 14 day prior entry trial . 8 . Uncontrolled congestive cardiac failure . 9 . Clinically active autoimmune disease . 10 . Dermatoses involve near tumor inject . Limb tumor may inject active dermatosis present limb . Trunk head neck tumor must inject dermatosis present within 50 cm tumor . 11 . Known test positive human immunodeficiency virus ( HIV ) , hepatitis B C syphilis . 12 . Patient injectable tumor potentially resectable case tumor necrosis swell . 13 . Previous history malignancy type occur recur within previous 5 year exception cone biopsied carcinoma cervix . 14 . Corticosteroid use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>gene transfer</keyword>
	<keyword>gene therapy</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>melanoma</keyword>
</DOC>